Immunovant Stock Analysis

Immunovant Stock Analysis Notes

About 56.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.21. Immunovant had not issued any dividends in recent years. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To learn more about Immunovant call the company at (917) 580-3099 or check out https://immunovant.com.

Immunovant Investment Alerts

Immunovant Upcoming and Recent Events

Immunovant Largest EPS Surprises

View All Earnings Estimates

Immunovant Environmental, Social, and Governance (ESG) Scores

Immunovant Stock Institutional Investors

Note, although Immunovant's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunovant Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.22 B.

Immunovant Profitablity

Management Efficiency

Immunovant has return on total asset (ROA) of (0.5454) % which means that it has lost $0.5454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9217) %, meaning that it created substantial loss on money invested by shareholders. Immunovant's management efficiency ratios could be used to measure how well Immunovant manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.0011 in 2024. Return On Capital Employed is likely to gain to -0.02 in 2024. Total Current Liabilities is likely to drop to about 27.1 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 386.8 M in 2024

Technical Drivers

As of the 29th of November, Immunovant retains the Risk Adjusted Performance of (0.02), standard deviation of 2.82, and Market Risk Adjusted Performance of (0.11). Immunovant technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Immunovant Price Movement Analysis

Immunovant Insider Trading Activities

Immunovant Outstanding Bonds

Immunovant Predictive Daily Indicators

Immunovant Corporate Filings

Immunovant Forecast Models

Immunovant's time-series forecasting models are one of many Immunovant's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunovant's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunovant prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunovant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunovant. By using and applying Immunovant Stock analysis, traders can create a robust methodology for identifying Immunovant entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunovant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunovant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Immunovant stock analysis indicators help investors evaluate how Immunovant stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunovant shares will generate the highest return on investment. By understating and applying Immunovant stock analysis, traders can identify Immunovant position entry and exit signals to maximize returns.

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.